COVID-19
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.SARS-Cov-2 infection (RT-PCR test or antigen dectection for SARS-CoV-2 was performed and it is positive) 2.At the time of visit or admission, no acute active bacterial infection was present (last blood routine: WBC < 10 ×10^9/L, N < 70%). 3. Fewer than 7 days since symptom onset or aggravation of pre-existing symptoms
Exclusion criteria
Exclusion criteria: 1.No Informed Consent; 2.Use of any type of antibiotic in the week prior to recruitment; 3.History of severe ventricular cardiac arrhythmia or electrocardiogram with corrected QT interval (QTc) =480 ms; 4.With severe liver disease (total bilirubin (TBIL) =2 times the upper limit of normal, alanine aminotransferase (ALT), aspartate aminotransferase (AST) =3 times the upper limit of normal); 5.Chronic renal failure (estimated glomerular filtration rate <30 mL/min/1.73 m2); 6.History of epilepsy; 7.History of myasthenia gravis; 8.Known allergy to quinolone; 9.Age: <18 years old; 10.Pregnant and lactating women or those who planned to have children during the trial period and within 6 months after the end of the trial; 11.People who are participating in other clinical trials or are using an investigational drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the incidence of bacterial superinfections within 28 days after COVID-19; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of Quinolone antibiotics-related adverse events and serious adverse events (D1-D28);all-cause mortality within 28 days;Duration of symptoms associated with COVID-19;The duration of hospital stay ;7-level ordinal scale at 7,14 and 28days (Compared with baseline); | — |
Countries
China
Contacts
Seventh Medical Center, Chinese PLA General Hospital